Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.

MLA

Zhang, Yang, et al. “Phase 1 Multicenter, Dose-Expansion Study of ARX788 as Monotherapy in HER2-Positive Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.” Cell Reports. Medicine, vol. 3, no. 11, Nov. 2022, p. 100814. EBSCOhost, https://doi.org/10.1016/j.xcrm.2022.100814.

APA

Zhang, Y., Qiu, M.-Z., Wang, J.-F., Zhang, Y.-Q., Shen, A., Yuan, X.-L., Zhang, T., Wei, X.-L., Zhao, H.-Y., Wang, D.-S., Zhao, Q., Xiong, G.-Z., Ji, Y.-P., Liang, X.-J., Xia, G., & Xu, R.-H. (2022). Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Reports. Medicine, 3(11), 100814. https://doi.org/10.1016/j.xcrm.2022.100814

Chicago

Zhang, Yang, Miao-Zhen Qiu, Ju-Feng Wang, Yan-Qiao Zhang, Ao Shen, Xiang-Lin Yuan, Tao Zhang, et al. 2022. “Phase 1 Multicenter, Dose-Expansion Study of ARX788 as Monotherapy in HER2-Positive Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.” Cell Reports. Medicine 3 (11): 100814. doi:10.1016/j.xcrm.2022.100814.